Clinical Trials · NCT06890611
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 125
- Start date
- Mar 2025
- Locations
- 1 site, United States
- Primary endpoint
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of Bimagrumab Test Material